1. Senology Newsletter Page 1 of 4
Senology.org - Newsletter
International Senologic and Oncologic Scientific Community (ISOSC)
"Connecting specialists worldwide"
Editor-in-Chief: Gian Paolo Andreoletti, MD
Subscribe Unsubscribe Contact Back Issues
Connecting Specialists Worldwide
SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US!
Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare,
Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for
real-time updates
Literature Selection
Kremer ME et al.: "Neglecting to screen women between the ages of 40 and 49 years with
mammography: what is the impact on breast cancer diagnosis?", AJR Am J Roentgenol. 2012
May;198(5):1218-22
Kalager M et al.: "Overdiagnosis of invasive breast cancer due to mammography screening: results
from the Norwegian screening program", Ann Intern Med. 2012 Apr 3;156(7):491-9
Berg WA et al.: "Detection of breast cancer with addition of annual screening ultrasound or a single
screening MRI to mammography in women with elevated breast cancer risk", JAMA. 2012 Apr 4;307
(13):1394-404
Vincent-Salomon A et al.: "High Ki67 expression is a risk marker of invasive relapse for classical
lobular carcinoma in situ patients", Breast. 2012 Apr 22. [Epub ahead of print]
Le Ray I et al.: "Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the
mastectomy rate in routine clinical practice. A population-based study with a median follow-up of
11years using propensity score matching", Eur J Cancer. 2012 Apr 16. [Epub ahead of print]
Smith GL et al.: "Association between treatment with brachytherapy vs whole-breast irradiation and
subsequent mastectomy, complications, and survival among older women with invasive breast
cancer", JAMA. 2012 May 2;307(17):1827-37
Chen WW et al.: "The impact of diabetes mellitus on prognosis of early breast cancer in Asia",
Oncologist. 2012 Apr;17(4):485-91
Ottini L et al.: "Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male
breast cancer patients: results from a collaborative multicenter study in Italy", Breast Cancer Res
Treat. 2012 Apr 18. [Epub ahead of print]
file://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012

2. Senology Newsletter Page 2 of 4
Discussion
- "Breast cancer screening with mammography " - Share your opinion on LinkedIn®
Focus on - CLEOPATRA trial
Baselga J et al.: "Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer", N Engl
J Med 2012 Jan 12;366(2):109-19
- CLEOPATRA trial
Calendar of Events
14th Milan Breast Cancer Conference, June 20-22, 2012, Milan, Italy
Benign Breast Diseases, Breast Cancer and Basic Science, June 27-30, 2012, Naoussa, Macedonia,
Greece
17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13,
2012, Salvador, Bahia, Brazil
8th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 15-17,
2012, Padova , Italy
Fragments of History
William S Halsted (New York, 1852-1922), "The results of radical operations for the cure of carcinoma
of the breast", Ann Surg. July 1907:46(1):1-19": “The Operation - (...) It must be our endeavor to trace
more definitely the routes travelled in the metastases to bone, particularly to the humerus, for it is even
possible in case of involvement of this bone that amputation of the shoulder joint plus a proper removal of the
soft parts might eradicate the disease. So, too, it is conceivable that ultimately, when our knowledge of the
lymphatics traversed in cases of femur involvement becomes sufficiently exact, amputation at the hip joint
may seem indicated"
Literature Selection
Smith AJ et al.: "Risk of cancer in first seven years after metal-on-metal hip replacement compared
with other bearings and general population: linkage study between the National Joint Registry of
England and Wales and hospital episode statistics", BMJ. 2012 Apr 3;344:e2383
Schlumberger M et al.: "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N
Engl J Med. 2012 May 3;366(18):1663-73
Seghir Z et al.: "CT screening for lung cancer brings forward early disease. The randomised Danish
Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT", Thorax.
2012 Apr;67(4):296-301
Ho YF et al.: "Oral Bisphosphonates and Risk of Esophageal Cancer: A Dose-Intensity Analysis in a
Nationwide Population", Cancer Epidemiol Biomarkers Prev. 2012 Apr 20. [Epub ahead of print]
Broughton T et al.: "Statin use is associated with a reduced incidence of colorectal cancer: a
colonoscopy-controlled case- control study", BMC Gastroenterol. 2012 Apr 24;12(1):36. [Epub ahead
of print]
Turati F et al.: "Family history of liver cancer and hepatocellular carcinoma", Hepatology. 2012 May;55
(5):1416-25
Giannini E et al.: "Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma
identified during surveillance in compensated cirrhosis", Hepatology. 2012 Apr 26 [Epub ahead of
print]
Kang J et al.: "A DNA Repair Pathway-Focused Score for Prediction of Outcomes in Ovarian Cancer
Treated With Platinum-Based Chemotherapy", J Natl Cancer Inst. 2012 Apr 13. [Epub ahead of print]
Tan HI et al.: "Long-term survival following partial vs radical nephrectomy among older patients with
early-stage kidney cancer", JAMA. 2012 Apr 18;307(15):1629-35
James ND et al.: "Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer", N
Engl J Med. 2012 Apr 19;366(16):1477-88
Leongamornlert D et al.: "Germline BRCA1 mutations increase prostate cancer risk", Br J Cancer.
2012 Apr 19. doi: 10.1038/bjc.2012.146. [Epub ahead of print]
Ahmed HU et al.: "Focal therapy for localised unifocal and multifocal prostate cancer: a prospective
development study", Lancet Oncol. 2012 Apr 16. [Epub ahead of print]
file://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012

3. Senology Newsletter Page 3 of 4
Comment
"Metformin in the treatment of pancreatic cancer", Donghui Li, Department of Gastrointestinal Medical
Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
"Patients with pancreatic cancer often have a high prevalence (80%) of concurrent diabetes or impaired
glucose tolerance, which are characterized by peripheral insulin resistance. Accumulating epidemiological
and experimental evidence suggest metformin, the most commonly used antidiabetic drug, as an antitumor
agent. In our retrospective study of 302 diabetic patients with pancreatic cancer, we observed that metformin
users had 4 months longer overall survival time, 32% reduced risk of death, and about 2-fold higher 2-year
survival rate than the nonmetformin group. These observations add supporting evidence for the antitumor
activity of metformin. Findings from this retrospective investigation should prompt future research to test the
hypothesis that metformin can be used as a supplemental therapy in the treatment of pancreatic cancer."
(Comment on: Sadeghi N et al.: "Metformin Use Is Associated with Better Survival of Diabetic Patients
with Pancreatic Cancer", Clin Cancer Res. 2012 Mar 31. [Epub ahead of print])
Literature Selection
Svejme O et al.: "Early menopause and risk of osteoporosis, fracture and mortality: a 34-year
prospective observational study in 390 women", BJOG. 2012 Apr 25 [Epub ahead of print]
Kotsopoulos j et al.: "Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation
carriers", Breast Cancer Res. 2012 ;14(2):R42. [Epub ahead of print]
Knoppert DC et al.: "The Effect of Two Different Domperidone Dosages on Maternal Milk Production",
J Hum Lact. 2012 May 3. [Epub ahead of print]
Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the
Expert Q&A Workshops and join the conversation.
TalkAboutHealth Q&A of the month
"In what cases should kidney cryoablation or radiofrequency ablation be considered to treat kidney
cancer? "
"Ablation is a new procedure for the treatment of kidney cancer that has even fewer complications
than laparoscopic or robotic surgery and also requires a much shorter recovery time. Until recently the
only treatment option for kidney tumors was to surgically remove them, either by removing the entire
kidney (radical nephrectomy) or by removing just the tumor and surrounding region of kidney (partial
nephrectomy). More recently, new technologies allow tumors to be destroyed, rendering them
essentially harmless, without them actually being removed. In one form of ablation, radiofrequency
energy is used to heat up and destroy the tumor. In another, known as cryoablation, the tumors are
frozen to very low temperatures (-40 degrees Celsius!) and thereby destroyed. It is not clear which
patients are the best candidates for ablation. In general, it seems the best candidates are patients with
tumors less than 4cm in size. Also, there is a small risk that the patient will require a second treatment,
which must be considered as well. Finally, the data on long-term outcomes are still being collected, so
patients who want the most “tried and true” methods might opt for a different procedure"
(Answer by Jaime Landman, Department of Urology,University of California, Irvine , CA, USA)
Unsubscribe
file://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012

4. Senology Newsletter Page 4 of 4
www.senology.org
file://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012